Program
Oct. 16-17, 2024, Wyndham Philadelphia Historic District.
Ready to Register?
Register now!
Program
Already registered?
Log into the virtual platform
Wednesday, Oct. 16
Registration, Poster Check In, Breakfast
7:30 – 8:30 a.m.
Poster Abstract Sessions
8 a.m. – 6:45 p.m.; Poster Hall - FDR Ballroom
- 11. Lentiviral Vector-based Polymeric Nanoparticles as Gene and Cell Therapy Product - A cross-functional Approach to Streamline and Control a Complex Manufacturing Process
Cecile Bauche, PhD, Alaya.bio
- 12. Towards Off-the-Shelf CAR-T Therapy: Lentiviral Vector-based Polymeric Nanoparticles for In Situ Gene Delivery into T-cells for Haematological Malignancies & Beyond
Cecile Bauche, PhD, Alaya.bio
- 13. An Optimal Pairing of scFv and Costimulatory Domain Regulates Dual CAR T Cell Signaling for Better Response Against B-ALL
Divanshu Shukla, PhD, University of Pennsylvania
- (Virtual) 15. Bone-Marrow-Homing Lipid Nanoparticles for Genome Editing in Leukemia and Leukemic Stem Cells
Xizhen Lian, Johns Hopkins University
- (Virtual) 16. A Novel Virus-Free Platform for Engineering CAR-T Cells with Enhanced Clinical Safety and Therapeutic Efficacy in Acute Lymphoblastic Leukemia
Philip Chiu-Tsun TANG, PhD, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
- (Virtual) 17. Efficient Combinatorial Adaptor-Mediated Targeting of Acute Myeloid Leukemia with CAR T-Cells
Laura Volta, PhD, University of Zurich Faculty of Medicine
- 18. Human Cord Blood-Derived Induced Pluripotent Stem Cells into Natural Killer Cells for Advanced Cancer Immunotherapy
Ranran Zhang, PhD, Catalent Cell and Gene Therapy
- 19. A Dual-Population CART Product for Safe and Effective Targeting of T-cell Malignancies
Ruchi Patel, PhD, Vittoria Biotherapeutics
- 20. The Simultaneous Measurement of Edit Associated Structural Variation and Transgene Localization in Single Cells
Christopher Tompkins, PhD, KromaTiD
- 21. Zip-Code Delivery: Creation of a Novel Nucleic Acid based Targeted Delivery System
Anthony Johnson, Kodikaz
- 22. INTASYL PH-894: Targeting BRD4 to Enhance NK Cell-Based Immunotherapy
Melissa Maxwell, Phio Pharmaceuticals
Poster Abstract Sessions
8 a.m. – 6:45 p.m.; Poster Hall - Betsy Ross Ballroom
- 23. Therapeutic Targeting of the CBS-CD73 Signaling Axis Attenuates Head and Neck Cancer Progression
Yong Teng, PhD, Emory University School of Medicine
- (Virtual) 24. mRNA-mediated Rescue of Lost Tumor Suppressor Function in Mutated p53 or BRCA1 Tumors is a Potent New Strategy for Cancer Therapy Delivered with Tumor-Targeted Peptide (non-LNP) Nanoparticles
Neil Desai, Aanastra Inc
- (Virtual) 25. In Vivo CRISPR Gene Editing of KRAS Mutant Tumors with Tumor-Targeted (non-LNP) Peptide-based Nanoparticles Causes Strong Tumor Regressions with Only 2 Doses and Overcomes Resistance to Existing Small-Molecule KRAS Inhibitors
Gilles Divita, PhD, DIVINCELL
- 26. Characterization and Preclinical Development of Tumor-Specific CRISPR/Cas9 Editing as a Combinatorial Therapy for Treatment-Resistant Solid Tumors
Kelly Banas, PhD, ChristianaCare
- 27. Focused Ultrasound Mediated Thermogenetic Control of CAR T Cell Activity in Breast Cancer Brain Metastasis
Chulyong Kim, Georgia Institute of Technology
- 28. Dual-targeting CD133/PD-L1 CAR-T Overcame Suppressive Microenvironment in Solid Tumor and Synergized with Radiotherapy and PD-1 Blockade
Kai Kang, MD, West China Hospital
- 29. A Platform for the Development of Personalized Oncolytic Adenoviruses
Fred Bunz, MD, PhD, Johns Hopkins University School of Medicine
- 30. Controlled, Riboswitch-Regulated Gene and Cell Therapy Targeting HER2+ Tumors
Xuecui Guo, MeiraGTx
- 31. Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs
Dolores Schendel, PhD, Medigene AG
- 32. T Cell Immune Characterization of the h-Met ß-Catenin Sleeping Beauty Model of HCC and its Therapeutic Response to Immune Checkpoint Blockade
Thanich Sangsuwannukul, PhD, Mayo Clinic
- (Virtual) 33. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Ramucirumab Clinical Trials
Adam Khan, Oklahoma State University
- (Virtual) 34. Single Cell Bioinformatics Uncovers a Novel T Cell Origin as Effective Immunotherapy for Solid Tumors
Max Kam-Kwan Chan, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong
- (Virtual) 35. In Vitro and In Vivo Lipid Nanocrystal (LNC) Delivery of Small Oligonucleotides and Small Molecules in Oncology
James Ferguson, MD, Matinas BioPharma
- 36. C/EBPß Drives Tumor Growth, Chemoresistance, and Immune Evasion Through the Stabilization of Senescent Secretory Cell Populations in the Tumor
Kevin Holm, City of Hope Beckman Research Institute
- 37. Addressing the HEK293 Host Cell Protein Monitoring Challenges for Viral Vector Gene Therapy Manufacturing
Olivia Kelada, Revvity Inc
- (Virtual) 38. A Novel Therapeutic Target of MDSC-dependent Immunosuppression in NSCLC
Siu Fan Jane Li, The Chinese University of Hong Kong
Welcome, Opening Remarks
8:30 – 8:35 a.m.
New Cancer-specific Antigens and Targeting of Intracellular Oncoproteins
8:35 – 10:20 a.m.
- New cancer-specific antigens and targeting of intracellular oncoproteins, CAR-based
Daniel Powell, PhD, University of Pennsylvania
- CAR T cell persistence - Balancing function and safety
Nayan Jain, PhD, Memorial Sloan Kettering Cancer Center
- Panel Discussion + Q&A
Break (Paid Presentation by Emit Imaging)
10:30 – 10:45 a.m.
Keynote Presentation
The Future of CAR-T Cells in Solid Tumors: Lessons Learned from Targeting Lymphoma
10:50 – 11:50 a.m.
- Barbara Savoldo, MD, PhD, University of North Carolina at Chapel Hill
Lunch + Exhibits
11:50 a.m. – 12:50 p.m.
Rational Combinations with Genetically Engineered Cells
12:55 – 2:10 p.m.
- A synthetic booster vaccine for chimeric antigen receptor T cells
Leyuan Ma, PhD, University of Pennsylvania
- Oncolytic viruses in combination with CAR-T cells
Richard Vile, PhD, Mayo Clinic
- Panel Discussion
Break
2:10 – 2:20 p.m.
CAR Integration and T Cell Malignancies
2:20 – 3:40 p.m.
- The biology and consequences of lentiviral integration: From HIV to engineered immune cells
Frederic Bushman, University of Pennsylvania
- Incidence of secondary malignancies in patients receiving CAR-T for lymphoma
Steven Schuster, MD, University of Pennsylvania
- Panel Discussion
Break
3:40 – 4:10 p.m.
Oral Abstract Presentations
CAR T Clinical Translation and Correlatives
4:10 – 5:25 p.m.
- 1. Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients with Pancreatic and Serous Epithelial Ovarian Cancer
Janos Tanyi, University of Pennsylvania
- 2. Combining CAR T Cell Therapy with Targeted Proton Beam Radiotherapy
Ugur Uslu, PhD, University of Pennsylvania
- 14. Engineering Allogeneic Cell Immunotherapies in a Single Intervention with the Innovative Pin-pointTM Base Editing Platform
Shannon Hinsdale, Revvity
- 4. Precision Biomaterials-Mediated Chronic Stimulation Sustains Supernumerary Expansion of Human CAR-T Cells In Vitro
Xiao Huang, Drexel University
- 5. Single Cell Analysis of Longitudinal CSF from Glioblastoma Patients Post Intrathecally Delivered EGFR-IL13Rα2 CAR T Therapy
Dana Silverbush, PhD, University of Pennsylvania School of Medicine
Poster Viewing, Exhibits, and Networking Reception
5:30 – 6:45 p.m.
Thursday, Oct. 17
Off the Shelf CAR-T Cells Using Direct In Vivo
8:30 – 10:15 a.m.
- Engineering G proteins on lentiviral vectors for T cell-targeted in vivo delivery of CAR constructs
Stephen Russell, MD, PhD, Vyriad
- In Vivo Engineering of Human Immune Cells
Tim Culp, PhD, Interius Biotherapeutics
- Direct in vivo gene transfer
Haig Aghajanian, PhD, Capstan
- Panel Discussion
Break
10:15 -10:45 a.m.
Oral Abstract Presentations
Novel Targets and Effector Cells
10:45 a.m. – 12 p.m.
- 6. Tracking CARs; Cell Surface Barcoding Novel Multi-targeted CAR T Cell Therapies for High Grade Gliomas
Ryan Cross, PhD, Walter and Eliza Hall Institute of Medical Research Immunology Division
- 7. The Augmentation of Smac Levels through an Armed Vesicular Stomatitis Virus Enhances Antitumor Immunity by Triggering PANoptosis
Yong Teng, PhD, Emory University School of Medicine
- 8. ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications
Shon Green, Adicet Therapeutics
- 9. Bioreducible LiPBAE miR-590-3p NanomiRs Inhibit Recurrent Glioblastoma Growth and Prolongs Survival
Hernando Lopez-Bertoni, PhD, Johns Hopkins School of Medicine
- 10. Tumor Associated Mitochondria Antigens (TAMAs) Vaccine Is Effective on Tumor and Tumor Associated Endothelial Cells: From the Mechanisms to the Clinical Validation
Francesca Costabile, PhD, University of Pennsylvania
Closing Remarks
12 – 12:10 p.m.
Ready to Register?
Register now!
Thank You to the Organizing Committee
- Chair: Saar Gill, MD, PhD
University of Pennsylvania
- Hans-Peter Kiem, MD, PhD
Fred Hutch
- Rayne Rouce, MD
Baylor College of Medicine
- Paula Cannon, PhD
University of Southern California
- Phillip Gregory, DPhil
Regeneron Cell Medicines
- Chiara Bonini, MD
Università Vita Salute San Raffaele
- Isabelle Riviere, PhD
Takeda Therapeutics